# A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

> **NCT06514742** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 101 (actual)

## Conditions studied

- Depressive Disorder, Major
- Anhedonia

## Interventions

- **DRUG:** Aticaprant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06514742
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-06-26
- **Primary completion:** 2025-04-08
- **Final completion:** 2025-04-24
- **Target enrollment:** 101 (ACTUAL)
- **Why stopped:** Early study termination due to insufficient efficacy.
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06514742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06514742, "A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06514742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*